Aneurysm, Congenital Heart Disease, Heart Valve Disease, Rheumatic Heart Disease
Conditions
Brief summary
It is well know that statins have been used to low cholesterol to prevent and treat coronary artery disease for many years. It was also reported that statins could protect endothelial function and cardiac function during coronary artery bypass graft. However, some results were controversial. Also, there is no clinical data available on statin cardiac protection during surgery in China where rheumatic heart disease is prevalent. Thus, the investigators are trying to see whether statins can protect heart injury during cardiac surgery in Chinese. Part of patients will receive statin treatment and part of will not before surgery in the study. Both patients' heart function will be measured and compared after surgery to determine whether statins can protect heart injury during heart surgery.
Detailed description
Cardiac function is crucial for cardiac surgery. The mortality remains very high in patients with poor cardiac function preoperation, long surgical time, complicate or difficult surgical procedure or uncompleted corrected malformation currently. Thus, it is necessary to search other approaches to improve cardiac function for cardiac surgery patients in order to increase the success, decrease complication and mortality in cardiac surgery. Although statin has been used to low cholesterol to prevent and treat coronary artery disease for many years, it has been reported that statin could protect endothelial function and cardiac function in coronary artery bypass graft. However, some results were controversy. Also, there is no clinical data available on statin cardiac protection during surgery in China where rheumatic heart disease is prevalence.Thus, it is necessary to perform a double blind, randomised clinical trial in China to determine whether statin can protect heart injury during heart surgery in China and what's its mechanism.
Interventions
DRUGSimvastatin
20 mg per day, start at 5 days before surgery and continue for one year. For some congenital heart diseases which other drugs such as digoxin, antistone, furosemide were prescribed less than half year, simvastatin will be prescribed less than half year.
Sponsors
Sun Yat-sen University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
10 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* cyanotic congenital heart disease * noncyanotic congenital heart disease with pulmonary hypertension * Heart valve disease, * other heart and great artery diseases need heart or great artery surgery
Exclusion criteria
* Coronary artery disease * under 10-year-old. * noncyanotic congenital heart disease without pulmonary hypertension * poor liver function such AST elevated,Hepatitis * Gestation women and Breast-feeding women
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| plasma troponin T level | within the first 7 days after surgery | The investigator will measure the plasma troponin T level in several time points before and after surgery in each patient. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| the index of B ultrasound on heart | one year after surgery | Each patient will be followed up and checked with B ultrasound on heart in 1,3,6 and 12 months after surgery. The index of B ultrasound on heart, such as ejection fraction, the diameter of left ventricle, will be measured |
Countries
China
Outcome results
None listed